Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 59 | 10.530 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 98 | 9.480 |
Why?
|
| Portal Vein | 30 | 2022 | 43 | 8.420 |
Why?
|
| Liver | 21 | 2022 | 127 | 6.660 |
Why?
|
| Liver Regeneration | 17 | 2022 | 24 | 4.850 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 106 | 3.330 |
Why?
|
| Ligation | 22 | 2022 | 36 | 2.430 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 41 | 2.230 |
Why?
|
| Laparoscopy | 6 | 2021 | 137 | 1.680 |
Why?
|
| Postoperative Complications | 13 | 2022 | 819 | 1.280 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 2 | 1.270 |
Why?
|
| Liver Diseases | 2 | 2018 | 30 | 1.100 |
Why?
|
| Cause of Death | 3 | 2017 | 50 | 1.040 |
Why?
|
| Registries | 9 | 2019 | 166 | 1.030 |
Why?
|
| Humans | 56 | 2024 | 22848 | 1.020 |
Why?
|
| Liver Failure | 4 | 2019 | 10 | 0.920 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 25 | 0.880 |
Why?
|
| Treatment Outcome | 20 | 2021 | 2960 | 0.870 |
Why?
|
| Hypoxia | 2 | 2020 | 28 | 0.790 |
Why?
|
| Hypertrophy | 5 | 2022 | 23 | 0.790 |
Why?
|
| Male | 36 | 2021 | 12453 | 0.760 |
Why?
|
| Organ Size | 9 | 2019 | 88 | 0.740 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3062 | 0.720 |
Why?
|
| Sarcopenia | 1 | 2021 | 26 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 24 | 0.670 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 89 | 0.660 |
Why?
|
| Middle Aged | 26 | 2019 | 7555 | 0.660 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 57 | 0.660 |
Why?
|
| Female | 31 | 2021 | 12677 | 0.630 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 9 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 227 | 0.610 |
Why?
|
| Hepatomegaly | 1 | 2018 | 6 | 0.610 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 4 | 0.600 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 53 | 0.600 |
Why?
|
| Publication Bias | 1 | 2018 | 4 | 0.590 |
Why?
|
| Oxidative Stress | 1 | 2018 | 81 | 0.590 |
Why?
|
| Antioxidants | 1 | 2018 | 56 | 0.580 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 96 | 0.580 |
Why?
|
| Bibliometrics | 1 | 2018 | 29 | 0.570 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 18 | 0.550 |
Why?
|
| Aged | 20 | 2019 | 7669 | 0.550 |
Why?
|
| Length of Stay | 5 | 2021 | 279 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 88 | 0.510 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.510 |
Why?
|
| Animals | 8 | 2021 | 3025 | 0.510 |
Why?
|
| Catheter Ablation | 1 | 2015 | 56 | 0.450 |
Why?
|
| Graft Rejection | 4 | 2008 | 51 | 0.450 |
Why?
|
| Liver Transplantation | 3 | 2015 | 79 | 0.430 |
Why?
|
| Prognosis | 8 | 2020 | 630 | 0.420 |
Why?
|
| Risk Factors | 10 | 2019 | 1942 | 0.420 |
Why?
|
| Time Factors | 9 | 2019 | 1220 | 0.420 |
Why?
|
| Hepatic Veins | 4 | 2022 | 9 | 0.410 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 53 | 0.400 |
Why?
|
| Feasibility Studies | 4 | 2016 | 157 | 0.380 |
Why?
|
| Survival Rate | 6 | 2018 | 270 | 0.350 |
Why?
|
| Operative Time | 4 | 2019 | 81 | 0.340 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1494 | 0.340 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 122 | 0.330 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 307 | 0.330 |
Why?
|
| Models, Animal | 3 | 2020 | 96 | 0.320 |
Why?
|
| Tissue Donors | 2 | 2021 | 66 | 0.320 |
Why?
|
| Random Allocation | 3 | 2018 | 114 | 0.320 |
Why?
|
| Isoantibodies | 2 | 2006 | 7 | 0.310 |
Why?
|
| Adult | 15 | 2019 | 6584 | 0.300 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 13 | 0.300 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 31 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 10 | 0.290 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 7 | 0.290 |
Why?
|
| Swine | 2 | 2018 | 62 | 0.290 |
Why?
|
| Death | 1 | 2008 | 36 | 0.290 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 13 | 0.280 |
Why?
|
| Patient Selection | 4 | 2018 | 157 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 150 | 0.280 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 99 | 0.270 |
Why?
|
| Rats, Wistar | 2 | 2017 | 43 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2019 | 485 | 0.270 |
Why?
|
| Rats | 2 | 2020 | 554 | 0.270 |
Why?
|
| Switzerland | 3 | 2021 | 7 | 0.260 |
Why?
|
| HLA Antigens | 1 | 2006 | 8 | 0.250 |
Why?
|
| Antibody Formation | 1 | 2006 | 12 | 0.250 |
Why?
|
| Plasmapheresis | 1 | 2006 | 12 | 0.250 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 3 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 5 | 0.220 |
Why?
|
| Spirituality | 1 | 2004 | 75 | 0.210 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 685 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 29 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2021 | 205 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 274 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 453 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2020 | 158 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 300 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 155 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 8 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 17 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2021 | 25 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 19 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 152 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 105 | 0.170 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 1 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 59 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 59 | 0.160 |
Why?
|
| Brazil | 2 | 2016 | 41 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 15 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2015 | 112 | 0.160 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.160 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.160 |
Why?
|
| Liver Function Tests | 4 | 2017 | 21 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 15 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2019 | 79 | 0.150 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 4 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2018 | 4 | 0.150 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 11 | 0.150 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 16 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 16 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 7 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 16 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2018 | 10 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 588 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 21 | 0.150 |
Why?
|
| Anesthesia | 1 | 2018 | 28 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 36 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 41 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 34 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 273 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 44 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 320 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 54 | 0.140 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 218 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 210 | 0.140 |
Why?
|
| Apoptosis | 1 | 2018 | 172 | 0.140 |
Why?
|
| Gastric Bypass | 1 | 2018 | 67 | 0.140 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.140 |
Why?
|
| Liver Circulation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 236 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 558 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2017 | 26 | 0.130 |
Why?
|
| Melanoma | 1 | 2017 | 50 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2017 | 17 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2018 | 354 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 10 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 155 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 477 | 0.130 |
Why?
|
| Obesity | 1 | 2018 | 263 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 7 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 7 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2017 | 1621 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 7 | 0.120 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 5 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.120 |
Why?
|
| Propofol | 1 | 2015 | 8 | 0.120 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 9 | 0.120 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 12 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 93 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 29 | 0.120 |
Why?
|
| Surgeons | 1 | 2016 | 80 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 77 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 5 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 9 | 0.100 |
Why?
|
| Viscera | 1 | 2013 | 2 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Renal Artery | 1 | 2013 | 6 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 6 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 25 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 41 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 61 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 205 | 0.100 |
Why?
|
| Bilirubin | 2 | 2016 | 11 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 2011 | 4 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 10 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 34 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 2 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 7 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 102 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 138 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 1 | 0.070 |
Why?
|
| Alemtuzumab | 1 | 2008 | 2 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 31 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 12 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 43 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 78 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 649 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 34 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 78 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4055 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 64 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2018 | 400 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 56 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1528 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 947 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 23 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 5 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2024 | 24 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2018 | 21 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 21 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1128 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 82 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 5 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 5 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 29 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 17 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 34 | 0.050 |
Why?
|
| Contrast Media | 1 | 2021 | 54 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 28 | 0.040 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 134 | 0.040 |
Why?
|
| United States | 2 | 2018 | 1726 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 4 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 102 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 214 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 12 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 50 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 23 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 16 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 6 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 187 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 90 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 76 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 977 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 13 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 38 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2017 | 28 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 317 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 24 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 138 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 99 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 71 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 166 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 657 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 72 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 175 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 305 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 13 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 7 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 57 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 12 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 270 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 76 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 377 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 241 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 470 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 337 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 8 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 500 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 14 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 64 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 49 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 305 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 8 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Child | 1 | 2012 | 990 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 2 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 16 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 238 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 6 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 39 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 74 | 0.020 |
Why?
|